SEC Form 4 · accession 0000899243-16-012927
IDEXX LABORATORIES INC /DE · IDXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian P McKeon
Officer — EVP, CFO and Treasurer
Period of report
Feb 5, 2016
Accepted (ET)
Feb 9, 2016 · 5:54 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874716
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 5, 2016 | M | 1,880 | $53.185 | A | 32,461 | D | |
| Common Stock | Feb 8, 2016 | M | 9,054 | $17.185 | A | 41,515 | D | |
| Common StockF2,F3 | Feb 8, 2016 | S | 4,200 | $69.1683 | D | 37,315 | D | |
| Common StockF2,F4 | Feb 8, 2016 | S | 4,854 | $70.0619 | D | 32,461 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right-to-buy)F7,F5 | $53.185 | Feb 5, 2016 | M | 1,880 | D | — | Dec 31, 2023 | Common Stock | 1,880 | 5,640 | D |
| Non-Qualified Stock Option (right-to-buy)F7,F6 | $17.185 | Feb 8, 2016 | M | 9,054 | D | — | Feb 13, 2016 | Common Stock | 9,054 | 0 | D |
Explanation of responses
- F1The number of securities reported reflects a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015 (the "Stock Split").
- F2Sale made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F3Represents the weighted average sales price of the shares sold ranging from a low of $68.73 to a high of $69.73 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F4Represents the weighted average sales price of the shares sold ranging from a low of $69.76 to a high of $70.33 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F5This option vests in five equal annual installments, beginning on the first anniversary date (01/01/2015) of the date of grant. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- F6Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,527 shares on February 14, 2010, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- F7Not applicable.